Hydrix Limited has launched the retail phase of its accelerated entitlement offer aiming to raise up to $8.18 million by issuing six new shares per existing share at $0.005 each, plus free options. The institutional component has closed, and retail shareholders have until 5 June to participate.
- Accelerated pro-rata entitlement offer to raise $8.18 million
- Six new shares issued per existing share at $0.005 each
- One free attaching option per new share exercisable at $0.01
- Retail offer open until 5 June 2026
- Peak Asset Management appointed lead manager
Retail Entitlement Offer Opens with Significant Upsize
Hydrix Limited (ASX:HYD) has kicked off the retail component of its accelerated pro-rata renounceable entitlement offer, targeting a total raise of approximately $8.18 million. The offer allows eligible retail shareholders to subscribe for six new shares at a price of $0.005 each for every existing share held, accompanied by one free attaching option exercisable at $0.01 and expiring in June 2029. This follows the closure of the institutional entitlement offer on 19 May 2026, which successfully raised $3.89 million and included a $5.1 million convertible note conversion, bolstering Hydrix’s balance sheet ahead of this retail phase.
Structure and Mechanics of the Offer
The entitlement offer is renounceable but rights will not be traded on ASX, limiting transferability. Eligible retail shareholders have received personalised offer documents and can apply for their entitlement via BPAY or EFT until 5 June 2026. Shareholders can apply for more than their entitlement; however, allocations of additional shares are not guaranteed. Unsubscribed entitlements from both institutional and retail tranches will be placed through a shortfall bookbuild managed by Peak Asset Management Pty Ltd, the lead manager appointed by Hydrix. Any premium from the sale of these entitlements will be returned to renouncing or ineligible shareholders, although there is no certainty of proceeds from this process.
Capital Raising in Context of Hydrix’s Business and Financial Position
This capital raise comes as Hydrix continues to advance its three core segments: embedded systems engineering for medtech and defence, venture investments in aligned technologies, and medical innovations focused on cardiovascular and connected healthcare. The recent institutional offer and debt conversion have provided a stronger financial footing, following a period of revenue decline and increased losses reported earlier in 2026. The company’s recent $1.2 million defence contract win and ongoing medical technology development underscore its strategic focus, but liquidity remains a key focus area. This entitlement offer aims to provide additional working capital to support these initiatives and manage liabilities.
Hydrix’s retail entitlement offer is open to shareholders registered in Australia and New Zealand, excluding those in the United States or acting for US persons. Ineligible shareholders will have their entitlements sold via the retail shortfall bookbuild, with proceeds remitted if a premium is achieved. This mechanism reflects a common approach for companies managing complex shareholder bases while raising capital.
Next Steps and Investor Considerations
Retail shareholders have until 5:00pm AEST on 5 June 2026 to participate. The company plans to announce retail offer results and any shortfall bookbuild outcomes by mid-June, with new shares and options expected to be issued shortly thereafter. Investors should note that the offer is not underwritten, so subscription risk remains. The use of proceeds has not been explicitly detailed in the announcement, leaving some uncertainty about the immediate impact on Hydrix’s operational capacity and growth trajectory.
Shareholders should consider the dilution impact of the offer, with up to 1.64 billion new shares potentially issued, significantly expanding the share base. The inclusion of free attaching options exercisable at a low strike price provides some potential upside if Hydrix’s share price recovers over the next three years.
Hydrix’s recent capital raising activities, including the institutional component and debt conversion, have been covered in detail in its prior $3.89M institutional entitlement offer and the company’s ongoing contract wins in defence and medtech sectors, such as the $1.2M defence contract, provide a backdrop for this raise. Investors will be watching how the company balances growth ambitions with financial discipline as it navigates these funding rounds.
Bottom Line?
Hydrix’s retail entitlement offer opens a critical funding window but leaves open questions on uptake and strategic deployment of capital amid ongoing financial pressures.
Questions in the middle?
- Will retail shareholders fully subscribe to the entitlement offer given the dilution and company’s recent financial performance?
- How will Hydrix prioritise the use of proceeds across its embedded systems, ventures, and medical segments?
- What premium, if any, will be achieved through the shortfall bookbuild for ineligible and renouncing shareholders?